Qiliqiangxin regulates the balance between tumor necrosis factor-α and interleukin-10 and improves cardiac function in rats with myocardial infarction

Cellular Immunology

Volumn 260, Issue 1, 2009, Pages 51-55

  Xiao, Hong ^a,b   Song, You ^a   Li, Ya ^a   Liao, Yu hua ^a   Chen, Jian ^a  

^a Union Hospital   (China)

^b NO1 Hospital of Wuhan   (China)

Author keywords

Cytokine; Interleukin 10; Myocardial infarction; Qiliqiangxin; Tumor necrosis factor

Indexed keywords

CARDIOVASCULAR AGENT; CHINESE DRUG; INTERLEUKIN 10; QILIQIANGXIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ACONITE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTRAGALUS PLANT; CONTROLLED STUDY; CYTOKINE RELEASE; DOWN REGULATION; DRUG MECHANISM; GINSENG; HEART FAILURE; HEART FUNCTION; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE PRESSURE; HEART RATE; HISTOPATHOLOGY; LYMPHOCYTE COUNT; MALE; NONHUMAN; ORANGE (FRUIT); PERIPLOCA; POLYGONATUM; PRIORITY JOURNAL; RAT; SAFFLOWER; SALVIA MILTIORRHIZA; SYSTOLIC BLOOD PRESSURE;

ANIMALS; DRUGS, CHINESE HERBAL; ECHOCARDIOGRAPHY; HEART; HEART FUNCTION TESTS; HEMODYNAMICS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-10; MALE; MYOCARDIAL INFARCTION; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR NECROSIS FACTOR-ALPHA;

RATTUS;

EID: 70350620702     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2009.09.001     Document Type: Article

References (20)

1. Wu Y.L., Gu C.H., Xu G.C., Wei C., and Gao X.D. Clinical observation of randomized double-blind and multicenter trial on Qiliqiangxin capsule in the treatment of chronic heart failure. Chinese Journal of Difficult and Complicated Cases 06 (2007) 55-58
2. Ling J.H., Wu P.B., Cai W.Y., Xu X.B., Zhuang M.R., and Li C.L. Therapeutic effect of Qiliqiangxin capsule on the patients with chronic congestive heart failure. Chinese Journal of Difficult and Complicated Cases 05 (2008) 49-55
3. Lisman K.A., Stetson S.J., Koerner M.M., Farmer J.A., and Torre-Amione G. The role of inflammation in the pathogenesis of heart failure. Current Cardiology Reports 4 3 (2002) 200-205
4. Gullestad L., and Aukrust P. The cytokine network in heart failure: pathogenetic importance and potential therapeutic targets. Heart Fail Monitor 2 1 (2001) 8-13
5. Torre-Amione G., Kapadia S., Lee J., et al. Tumor necrosis factor-α and tumor necrosis factor receptors in the failing human heart. Circulation 93 (1996) 704-711
6. Yang Z., Zingarelli B., and Szabo C. Crucial role of endogenous interleukin-10 production in myocardial ischemia/reperfusion injury. Circulation 101 (2000) 1019-1026
7. De Waal Malefyt R., Abrams J., Bennett B., Figdor C.G., and de Vries J.E. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. The Journal of Experimental Medicine 174 (1991) 1209-1220
8. Cheng X., Liao Y.H., Ge H., et al. Effects of early treatment with metoprolol on myocardial inflammatory cytokine expression and heart function in rats with acute myocardial infarction. Journal of Clinical Immunology 25 3 (2005) 246-253
9. Diwan A., Tran T., Misra A., and Mann D.L. Inflammatory mediators and the failing heart: a translational approach. Current Molecular Medicine 3 2 (2003) 161-182
10. Li B., Liao Y.H., Cheng X., Ge H., Guo H., and Wang M. Effects of carvedilol on cardiac cytokines expression and remodeling in rat with acute myocardial infarction. International Journal of Cardiology 111 2 (2006) 247-255
11. Satoh M., Nakamura M., Saitoh H., et al. Tumor necrosis factor-alpha-converting enzyme and tumor necrosis factor-alpha in human dilated cardiomyopathy. Circulation 25 (1999) 3260-3265
12. Mann D.L., McMurray J.J., Packer M., et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 109 (2004) 1594-1602
13. Chung E.S., Packer M., Lo K.H., Fasanmade A.A., and Willerson J.T. Anti-TNF therapy against congestive heart failure investigators. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 107 (2003) 3133-3140
14. Aukrust P., Muller F., Ueland T., et al. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation 100 6 (1999) 614-620
15. Kaur K., Sharma A.K., and Singal P.K. Significance of changes in TNF-α and IL-10 levels in the progression of heart failure subsequent to myocardial infarction. American Journal of Physiology-Heart and Circulatory Physiology 291 (2006) H106-H113
16. Zhao Z., Wang W., Wang F., et al. Effects of Astragaloside IV on heart failure in rats. Chinese Medicine 4 (2009) 6
17. Ryu M., Kim E.H., Chun M., et al. Astragali Radix elicits anti-inflammation via activation of MKP-1, concomitant with attenuation of p38 and Erk. Journal of Ethnopharmacology 115 2 (2008) 184-193
18. Zhao P., Su G., Xiao X., Hao E., Zhu X., and Ren J. Chinese medicinal herb Radix Astragali suppresses cardiac contractile dysfunction and inflammation in a rat model of autoimmune myocarditis. Toxicology Letter 182 (2008) 29-35
19. Lin J.S., Chan C.Y., Yang C., Wang Y.H., Chiou H.Y., and Su Y.C. Zhi-fuzi, a cardiotonic Chinese herb, a new medical treatment choice for portal hypertension. Experimental Biology and Medicine 232 4 (2007) 557-564
20. Zhu W.H., Leng X.S., and Zhu J.Y. Effect of Shenfu injection on ischemia-reperfusion injury of rat liver graft. Hepatobiliary and Pancreatic Diseases International 5 2 (2006) 205-209